| Title |
A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, May 2014
|
| DOI | 10.1007/s10549-014-2986-7 |
| Pubmed ID | |
| Authors |
A. Lintermans, K. Van Asten, H. Wildiers, A. Laenen, R. Paridaens, C. Weltens, J. Verhaeghe, D. Vanderschueren, A. Smeets, E. Van Limbergen, K. Leunen, M. R. Christiaens, P. Neven |
| Abstract |
Aromatase inhibitor (AI) therapy for estrogen receptor-positive breast cancer is known to induce or enhance musculoskeletal problems. We have previously reported that loss of grip strength is more pronounced in AI-users with extremes in BMI. We here report results from a larger prospective study. Postmenopausal early breast cancer patients scheduled to start AI or tamoxifen therapy were recruited. A functional assessment grip strength test was performed at baseline, 3, 6, and 12 months of therapy. BMI was assessed, and a rheumatologic questionnaire was completed at each visit. 188 patients on an AI and 104 patients on tamoxifen were enrolled. 74 % of AI-users reported new/worsened musculoskeletal complaints compared with 37 % in the tamoxifen group. This was translated in a larger grip strength decrease in patients experiencing AI-induced pain opposed to patients without new/worsened complaints (p = 0.0002). 15 % of AI-users discontinued therapy due to musculoskeletal symptoms, who were characterized by a larger grip strength reduction versus adherent patients (p = 0.0107). Young age (p = 0.0135), taxane-based chemotherapy (p = 0.0223), and baseline VAS score >4 (p = 0.0155) were predictors for AI-related musculoskeletal pain. In addition, a quadratic trend of BMI with grip strength change (p = 0.0090) and probability of discontinuation was observed (p = 0.0424). Musculoskeletal events were a substantial problem in AI-treated patients and an important reason for treatment discontinuation. The decrease in grip strength was larger in AI- than in tamoxifen-users, with a more pronounced change in symptomatic patients. The inverse relationship between BMI extremes and grip strength change was confirmed in this large group of AI-patients. |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Turkey | 1 | 1% |
| Unknown | 78 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 16 | 20% |
| Student > Ph. D. Student | 15 | 19% |
| Student > Bachelor | 11 | 14% |
| Researcher | 5 | 6% |
| Student > Doctoral Student | 4 | 5% |
| Other | 14 | 18% |
| Unknown | 15 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 34% |
| Nursing and Health Professions | 7 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Psychology | 5 | 6% |
| Sports and Recreations | 4 | 5% |
| Other | 12 | 15% |
| Unknown | 19 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 May 2014.
All research outputs
#20,229,658
of 22,755,127 outputs
Outputs from Breast Cancer Research and Treatment
#4,104
of 4,652 outputs
Outputs of similar age
#193,016
of 227,133 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#59
of 68 outputs
Altmetric has tracked 22,755,127 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,652 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 227,133 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.